Quantbot Technologies LP Nurix Therapeutics, Inc. Transaction History

Quantbot Technologies LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$9.86 - $14.59 $81,650 - $120,819	-8,281 Reduced 96.29%	319 $3,000
Q3 2022 Nov 07, 2022	BUY	$12.33 - $19.81 $93,708 - $150,556	7,600 Added 760.0%	8,600 $112,000
Q2 2022 Aug 09, 2022	SELL	$7.88 - $14.82 $36,248 - $68,172	-4,600 Reduced 82.14%	1,000 $12,000
Q1 2022 May 16, 2022	BUY	$12.94 - $29.65 $49,172 - $112,670	3,800 Added 211.11%	5,600 $78,000
Q4 2021 Feb 11, 2022	SELL	$26.43 - $34.5 $137,436 - $179,400	-5,200 Reduced 74.29%	1,800 $52,000
Q3 2021 Nov 09, 2021	BUY	$22.71 - $36.69 $154,428 - $249,491	6,800 Added 3400.0%	7,000 $209,000
Q2 2021 Aug 12, 2021	BUY	$24.21 - $35.89 $4,842 - $7,178	200 New	200 $5,000

180

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $860M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.